Loading…
Employees: 485
Size Ginkgo Bioworks (DNA) is a United States Health Care company (Medical/Nursing Services) with a market value of $760M, the 2427th largest of 3,117 United States companies the cockpit tracks. Shares closed at $11.29 on 6 Nov 2026.
Performance Over six months the shares gained 26.4%, against -0.2% for the median peer and -1.1% for the United States market (cap-weighted) — 4th highest of 20 in its peer set.
Growth Revenue fell 51.5% over the last twelve months (peer median +7.0%); the operating margin is -258.0% (peer median 7.9%).
Valuation It trades at 7.7× enterprise value to sales against a peer median of 1.6× (3rd most expensive of 21).
Capital Return on invested capital runs 54.7 points below its cost of capital (10.8% WACC).
Backlog Backlog (remaining performance obligations) was $113M at 30 Jun 2026, up 11% on a year earlier — 0.9 years of trailing revenue. Backlog detail →
Short interest Short interest is 15.0% of the free float (15 Oct 2026).
Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $112M | $170M | $227M | $251M | $478M |
| Revenue growth | — | -25% | -10% | -47% | — |
| Gross profit | $38.7M | $82.9M | $137M | $143M | $212M |
| EBITDA | -$236M | -$255M | -$397M | -$601M | -$2.10B |
| Net income | -$315M | -$313M | -$547M | -$893M | -$2.10B |
| Free cash flow | -$175M | -$179M | -$382M | -$336M | -$304M |
| Capital expenditure | $4.56M | $7.67M | $62.5M | $40.8M | $52.3M |
| Total debt | $404M | $440M | $468M | $242M | $443M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | DNA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -0.4% | -2.2% | 10th highest of 21 |
| 6-month return | +26.4% | -0.2% | 4th highest of 20 |
| Distance from 52-week high | -38.0% | -21.4% | 5th lowest of 21 |
| Revenue growth (TTM) | -51.5% | +7.0% | lowest of 21 |
| Operating margin | -258.0% | 7.9% | lowest of 21 |
| EV / Sales | 7.7× | 1.6× | 3rd most expensive of 21 |
| ROIC minus cost of capital | -54.7 pp | -1.0 pp | lowest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Ginkgo Bioworks DNA | United States | $760M | +26% | -52% | -258% | 7.7× | n/a | n/a |
| WELL Health Technologies WELL.TO | Canada | $760M | -5% | +39% | 7% | 1.4× | 9.1% | +94.5% |
| HK inno.N 195940.KS | South Korea | $745M | -32% | +7% | 12% | 0.9× | -10.8% | +12.2% |
| Jinxin Fertility 1951.HK | Hong Kong | $800M | -2% | +7% | 11% | 2.9× | 18.0% | +12.4% |
| Thyrocare Technologies THYROCARE.NS | India | $830M | +5% | +22% | 26% | 8.3× | 27.9% | +10.9% |
| GMR Solutions GMRS | United States | $672M | n/a | -4% | 14% | 0.9× | -20.0% | -4.0% |
| Terveystalo Oy TTALO.HE | Finland | $883M | -19% | -8% | 8% | 1.2× | -4.6% | +5.3% |
| Fulgent Genetics FLGT | United States | $653M | +49% | +7% | -36% | 1.2× | n/a | n/a |
| BML 4694.T | Japan | $887M | -2% | +4% | 7% | 0.6× | -9.7% | +1.6% |
| Nephrocare Health Services NEPHROPLUS.NS | India | $639M | +10% | +33% | 14% | 5.8× | 35.7% | +31.6% |
| Shanghai Labway Clinical Laboratory 301060.SZ | China | $593M | -4% | -19% | 6% | 2.7× | 8.8% | +3.2% |
| AdaptHealth AHCO | United States | $1.00B | +8% | -3% | 3% | 0.9× | 16.3% | +25.2% |
| Regis Healthcare REG.AX | Australia | $1.05B | -17% | +17% | 4% | 1.0× | 14.6% | +14.4% |
| Novogene 688315.SS | China | $1.16B | +31% | +6% | 7% | 2.6× | 17.1% | +8.2% |
| Strata Critical Medical SRTA | United States | $497M | 0% | +23% | -4% | 1.6× | n/a | n/a |
| GoodRx GDRX | United States | $1.20B | +20% | -2% | 12% | 1.8× | 6.8% | +7.7% |
| JS Link 127120.KS | South Korea | $481M | -57% | +51% | -76% | 28.2× | n/a | n/a |
| Nutex Health NUTX | United States | $1.24B | +32% | +7% | 43% | 1.8× | -19.5% | +253.5% |
| Metropolis Healthcare METROPOLIS.NS | India | $1.25B | +12% | +20% | 18% | 6.6× | 32.4% | +10.5% |
| Pennant PNTG | United States | $1.27B | +1% | +38% | 6% | 1.6× | 21.1% | +19.4% |
| Integral Diagnostics IDX.AX | Australia | $450M | -21% | +26% | 9% | 1.5× | 8.3% | +17.7% |
Ginkgo Bioworks reported $113M of remaining performance obligations at 30 Jun 2026, up 11% from a year earlier and down 11% from the previous quarter. That is 0.9 years of trailing revenue already under contract. Book-to-bill last quarter: 0.29.